Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

These Stocks Are Surging but See Which Ones Hedge Funds Think are Worth Investing In

Page 1 of 2

The markets have been advancing on Friday after an encouraging speech from the Fed’s Janet Yellen, who said that there is a high probability that the interest rates will be increased this year, which ensured the investors about the Fed’s confidence in the economy. However, among the overall uptrend, several companies managed to stand above the crowd, registering gains that go as much as over 80% boost of the Bellerophon Therapeutics Inc (NASDAQ:BLPH)‘s stock. In this article, we will take a closer look at some of the top gainers on Friday and will see whether the smart money have been as bullish on them as the overall market today.

Teva Pharmaceuticals TEVA Drugs

The smart money sentiment is a metric that is often overlooked, but our research has shown that hedge funds are actually the perfect investors to emulate due to their extensive analysis and great skills in picking stocks. However, hedge funds on average have been lagging the market lately due to their large sizes, which forces them to trade returns for less risk, but they still generate solid returns on the long side of their portfolios. Through extensive backtests that span through the period between 1999 and 2012, we determined that hedge funds’ top small-cap ideas can outperform the market over the long term. Based on these results, we launched our small-cap strategy that involves imitating top 15 small-cap stocks among over 700 hedge funds in August 2012 and it has returned over 118% since then, beating the market by over 60 percentage points (read more details here).

In this way, let’s take a closer look at the Friday intraday gainers, starting with Bellerophon Therapeutics Inc (NASDAQ:BLPH), which surged the most today, although despite the 80% boost, it is still down by 24% year-to-date. Nevertheless, the news that sparked the gain signal also a potential for the long-term as it involved the announcement of positive data from the company’s Phase 2 study of INOpulse for the treatment of Pulmonary Arterial Hypertension. Bellerophon, a developer of bio-therapeutic drugs, has also received a Special Protocol Assessment for its Phase 3 program from the US Food and Drug Administration.

Follow Bellerophon Therapeutics Inc. (NASDAQ:BLPH)
Trade (NASDAQ:BLPH) Now!

Even though Bellerophon Therapeutics Inc (NASDAQ:BLPH) is not very popular among the funds we track, the six funds that disclosed stakes as of the end of June amassed nearly 45% of the company. Moreover, as the number of funds with long positions in the company declined by one between April and June, the aggregate value of their holdings fell to $45.99 million from $54.72 million. Nevertheless, the largest position among these investors is held by Steven B. Klinsky‘s New Mountain Capital, which disclosed ownership of 4.86 million shares worth $38.53 million, representing the last of the fund’s three holdings. Baker Bros. Advisors is also bullish on the company, owning 350,000 shares as of the end of the second quarter.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!